Literature DB >> 7540373

Interaction of osteopontin with osteoclast integrins.

M A Horton1, M A Nesbit, M H Helfrich.   

Abstract

Mammalian osteoclasts express three integrin receptors--alpha v beta 3 (vitronectin receptor), alpha 2 beta 1 and alpha v beta 1. The vitronectin receptor recognizes bone matrix proteins, including bone sialoproteins, in an RGD-dependent manner, whereas adhesion to collagen involves beta 1 integrins. Interference with integrin function, by anti-receptor antibodies or RGD-peptides, blocks bone resorption. Data on the mechanism of osteoclast adhesion to sialoproteins and the differential synthesis of osteopontin and bone sialoprotein by osteoclasts is presented. Thus, osteoclasts adhere to both osteopontin and bone sialoprotein with a characteristic irregular morphology with numerous, peripherally placed, actin-rich podosomes. Adhesion is predominantly RGD and beta 3 dependent, though alpha v beta 1 may also be involved in adhesion to bone sialoprotein. KQAGD and AGDV, but not H12, fibrinogen peptides induce osteoclast 'rounding' on osteopontin suggesting there is an alternative anti-adhesive signal to 'RGD.' However, adhesion is not completely inhibited and is not specific for osteopontin as equivalent effects are seen with adhesion to serum. The role of sialoproteins in osteoclast adhesion in situ in the skeleton is complicated by the finding of endogenous synthesis of osteopontin, but not bone sialoprotein, by osteoclasts. The disposition of osteoclast integrins during resorption and the role of integrins and sialoprotein-derived peptides in osteoclast adhesion and function is also reviewed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540373     DOI: 10.1111/j.1749-6632.1995.tb44630.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

1.  The isolation and characterization of glycosylated phosphoproteins from herring fish bones.

Authors:  Hai-Yan Zhou; Erdjan Salih; Melvin J Glimcher
Journal:  J Biol Chem       Date:  2010-09-10       Impact factor: 5.157

2.  Osteoclast responses to lipopolysaccharide, parathyroid hormone and bisphosphonates in neonatal murine calvaria analyzed by laser scanning confocal microscopy.

Authors:  Keiko Suzuki; Sadaaki Takeyama; Takashi Kikuchi; Shoji Yamada; Jaro Sodek; Hisashi Shinoda
Journal:  J Histochem Cytochem       Date:  2005-08-08       Impact factor: 2.479

3.  Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment.

Authors:  T-I Chiang; I-C Chang; H-S Lee; H Lee; C-H Huang; Y-W Cheng
Journal:  Osteoporos Int       Date:  2010-08-24       Impact factor: 4.507

4.  Increased serum osteopontin is a risk factor for osteoporosis in menopausal women.

Authors:  I-C Chang; T-I Chiang; K-T Yeh; H Lee; Y-W Cheng
Journal:  Osteoporos Int       Date:  2010-03-18       Impact factor: 4.507

Review 5.  Oral fluid-based biomarkers of alveolar bone loss in periodontitis.

Authors:  Janet S Kinney; Christoph A Ramseier; William V Giannobile
Journal:  Ann N Y Acad Sci       Date:  2007-03       Impact factor: 5.691

6.  Modulation of bone resorption by phosphorylation state of bone sialoprotein.

Authors:  Paul Curtin; Kevin P McHugh; Hai-Yan Zhou; Rudolf Flückiger; Paul Goldhaber; Frank G Oppenheim; Erdjan Salih
Journal:  Biochemistry       Date:  2009-07-28       Impact factor: 3.162

7.  Rho-ROCK signaling differentially regulates chondrocyte spreading on fibronectin and bone sialoprotein.

Authors:  Kamal S Gill; Frank Beier; Harvey A Goldberg
Journal:  Am J Physiol Cell Physiol       Date:  2008-05-07       Impact factor: 4.249

8.  Octacalcium phosphate collagen composite stimulates the expression and activity of osteogenic factors to promote bone regeneration.

Authors:  Atsumu Kouketsu; Keiko Matsui; Tadashi Kawai; Yushi Ezoe; Toshiki Yanagisawa; Ayato Yasuda; Tetsu Takahashi; Shinji Kamakura
Journal:  J Tissue Eng Regen Med       Date:  2019-11-12       Impact factor: 3.963

Review 9.  Recent Progress of RGD Modified Liposomes as Multistage Rocket Against Cancer.

Authors:  Afsana Sheikh; Nabil A Alhakamy; Shadab Md; Prashant Kesharwani
Journal:  Front Pharmacol       Date:  2022-01-25       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.